Clinical Trial

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 19, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer. The main questions it aims to answer are: * The efficacy of this combination in R/M/P CC; * The tolerance of this combination in R/M/P CC; * Possible biomarker of treatment response for this combination. Participants will receive cadonilimab of 10mg/kg every three weeks at day 1, take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break and subcutaneously injection of GM-CSF (200ug) from day 1 to day 14, then also take a 7-days break. This treatment will continue until progression or intolerable toxicity or withdraw of participants and it will last for no longer than 2 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-05.
Trial Details
NCT Number NCT05817214
Lead Sponsor Zhongnan Hospital
Collaborators: Akeso Biopharma Co., Ltd.
Conditions Cervical Cancer
Enrollment 35 participants
Start Date 2023-02-16
Primary Completion 2025-11-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-04-19